Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease.

Trial Profile

Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2012 Actual end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual patient number changed from 330 to 329 as reported by ClinicalTrials.gov.
    • 19 Oct 2011 Actual number of patients reported by ClinicalTrials.gov (n=330).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top